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Abstract
Introduction: Postmenopausal patients with rheumatoid arthritis (RA) are often treated with corticosteroids. Loss of
estrogen, the inflammatory disease and exposure to corticosteroids all contribute to the development of
osteoporosis. Therefore, our aim was to investigate if addition of the selective estrogen receptor modulator
raloxifene, or estradiol, could prevent loss of bone mineral density in ovariectomized and dexamethasone treated
mice with collagen-induced arthritis (CIA).
Methods: Female DBA/1-mice were ovariectomized or sham-operated, and CIA was induced. Treatment with
dexamethasone (Dex) (125 μg/d), estradiol (E2) (1 μg/d) or raloxifene (Ral) (120 μg/day) alone, or the combination of
Dex + E2 or Dex + Ral, was started after disease onset, and continued until termination of the experiments. Arthritic
paws were collected for histology and one of the femoral bones was used for measurement of bone mineral density.
Results: Dex-treatment alone protected against arthritis and joint destruction, but had no effect on osteoporosis in
CIA. However, additional treatment with either Ral or E2 resulted in completely preserved bone mineral density.
Conclusions: Addition of raloxifene or estradiol to dexamethasone-treatment in experimental postmenopausal
polyarthritis prevents generalized bone loss.
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Introduction
Rheumatoid arthritis (RA) is a progressive systemic auto-
immune disease with a prevalence of about 0.5 to 1% [1]
and it is characterized by symmetrical polyarthritis. Sev-
eral findings indicate the involvement of sex hormones in
RA. For example, the female to male incidence ratio is 4
to 5:1 before 50 years of age, and 2:1 for patients with a
later onset [1,2], and the peak incidence in women coin-
cides with the onset of menopause [3]. Chronic inflam-
mation leads to destruction of joint cartilage and
periarticular bone, as well as the development of general-
ized bone loss. The prevalence of osteoporosis is more
than 50% in postmenopausal patients with RA [4,5].
Glucocorticoid treatment is often used to suppress
inflammation in autoimmune diseases [6], but unfortu-
nately prolonged use of glucocorticoids is associated with
the development of osteoporosis and increased risk of
fractures [7]. Hormone replacement therapy (HRT) is
used to treat postmenopausal osteoporosis, and to com-
pensate for the loss of natural hormones, but it is no
longer recommended for long-term therapy due to the
risk of serious side effects. However, HRT has also been
shown to ameliorate RA, with decreased joint destruc-
tion, reduced inflammation, increased bone mineral den-
sity (BMD), and better patient health assessment [8].
Raloxifene (Ral) is a selective estrogen receptor modula-
tor (SERM) approved for the treatment of patients with
postmenopausal osteoporosis [9], and in the USA it is
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[ 1 0 ] .W eh a v ep r e v i o u s l ys h o w nt h a tt r e a t m e n tw i t hR a l
or 17b-estradiol (E2) results in a reduced frequency of
collagen-induced arthritis (CIA), suppressed disease
severity, preserved joint histology, and maintained BMD
[11]. These effects are also seen during long-term treat-
ment, when therapy is started in patients with already
established disease [12].
In this study we investigated the effects of combined
treatment with Ral and glucocorticoids, or estradiol and
glucocorticoids, on the development of arthritis and
osteoporosis. CIA is a well-established animal model
resembling RA [13]. CIA was induced in female mice
that were either sham-operated or had been ovariecto-
mized in order to assimilate a postmenopausal status in
h u m a n s .W eh a v ep r e v i o u s l ys h o w nd e c r e a s e dt r a b e c u -
lar BMD in arthritic OVX mice, compared with arthritic
mice with preserved endogenous estrogen production
[14]. In this study, we found that treatment with the
corticosteroid dexamethasone (Dex) protects against
joint destruction and ameliorates the clinical signs of
arthritis, although it does not prevent bone loss. How-
ever, the addition of Ral or E2 to the Dex treatment
results in completely preserved BMD and protects from
osteoporosis.
Materials and methods
Mice
The ethical committee for animal experiments at
Gothenburg University approved this study. Female
DBA/1 mice (TaconicM&B A/S, Ry, Denmark) were
electronically tagged and kept, 5 to 10 animals per cage,
under standard environmental conditions, and fed stan-
dard laboratory chow and tap water ad libitum.
Ovariectomy
Ovarietomy (OVX) and sham operation were performed
at 9 to 10 weeks of age. Ovaries were removed through a
midline incision of the skin, and flank incisions of the
peritoneum. The skin incision was then closed with
metallic clips. Sham-operated animals had their ovaries
exposed but not removed. Surgery was performed after
the mice were anesthetized with ketamine (PfizerAB,
Täby, Sweden) and medetomidin (OrionPharma, Espoo,
Finland), or during Isofluran inhalation (Isofluran Baxter,
Baxter Medical AB, Kista, Sweden). Carprofen (Orion-
Pharma, Sollentuna, Sweden) was used as post-operative
pain relief.
Induction and evaluation of arthritis
One to two weeks after surgery the mice were immu-
nized with 100 μg chicken collagen type II (CII) (Sig-
maAldrich, St Louis, MO, USA) dissolved in 0.1 M acetic
acid and emulsified with an equal volume of incomplete
Freund’s adjuvant (SigmaAldrich, St Louis, MO, USA)
supplemented with 0.5 mg/ml Mycobacterium tuberculo-
sis (SigmaAldrich, St Louis, MO, USA). A total volume of
100 μl was injected subcutaneously at the base of the tail.
Twenty one days after the first immunization, mice
received a booster injection with CII emulsified in incom-
plete Freund’s adjuvant. The animals were evaluated
e v e r yt w ot ot h r e ed a y sf o rf r e q u e n c ya n ds e v e r i t yo f
arthritis until termination of the experiments. Arthritis
was considered present when signs of arthritis were iden-
tified in one joint for two consecutive assessments, or in
more than one joint. Scoring was performed in a blinded
way without knowledge of the previous scores. Severity
was graded as described previously [15], scoring 1 to 3 in
each paw (maximum of 12 points per mouse) as follows:
1, swelling or erythema in one joint; 2, swelling or
erythema in two joints; 3, severe swelling of the entire
paw or ankylosis.
Hormones and treatment
Mice were given intraperitoneal (ip) injections five days
per week of the synthetic corticosteroid Dex (Oradexon
®,
Organon, Gothenburg, Sweden) (125 μg/mouse/day) dis-
solved in 0.9% sodium chloride (NaCl), subcutaneous (sc)
injections of E2 (SigmaAldrich, St Louis, MO, USA) (1.0
μg/mouse/day) dissolved in Miglyol 812 (OmyaPeralta
GmbH, Hamburg, Germany), or sc injections of Ral (Sig-
maAldrich, St Louis, MO, USA) (120 μg/mouse/day) dis-
solved in Miglyol 812. Control mice received ip and sc
injections of 0.9% NaCl (100 μl/mouse/day) and Miglyol
812 (100 μl/mouse/day), respectively. Treatment with Dex,
E2, Ral, or vehicle was started when the first mice had
started to develop arthritis (day 22 to 23), and continued
until termination of the experiments (day 44 to 49).
Tissue collection and histologic examination
At the termination of the experiments, mice were
anesthetized for blood withdrawal, and then euthanized
by cervical dislocation. Sera were individually collected
and stored at -20°C until used. Successful removal of
the ovaries at the castration procedure was confirmed
by weighing the uteri. One femur was placed in 70%
ethanol for analysis of BMD, and the other was used for
flow cytometry of bone marrow cells. Paws were placed
in 4% paraformaldehyde, decalcified, and embedded in
paraffin. Sections were stained with H&E and encoded
before examination. In sections from each animal, the
proximal and distal parts of all four paws were graded
separately on a scale of 0 to 4, with the score then
divided by two, which yielded a maximum histologic
destruction score of 16 points per mouse, assessed as
follows: 1 = synovial hypertrophy, 2 = pannus, erosions
of cartilage, 3 = erosions of bone, 4 = complete
ankylosis.
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One femur was subjected to a peripheral quantitative
computed tomography (pQCT) scan with a Stratec pQCT
XCT Research M, software version 5.4B (Norland, Fort
Atkinson, WI) at a resolution of 70 μm, as described pre-
viously [16]. Trabecular BMD was determined with a
metaphyseal scan at a point 3% of the length of the femur
from the growth plate. The inner 45% of the area was
defined as the trabecular bone compartment.
Serologic markers of cartilage and bone remodelling
For measurement of cartilage destruction, serum levels of
cartilage oligomeric matrix protein (COMP) were deter-
mined with an Animal COMP
® ELISA kit (AnaMar Medi-
cal AB, Uppsala, Sweden) according to the manufacturer’s
instructions. Bone resorption was assessed by serum levels
of type I collagen fragments using the RatLaps ELISA kit
(Nordic Bioscience Diagnostics, Herlev, Denmark) accord-
ing to the manufacturer’s instructions. The detection lim-
its for COMP and RatLaps were 2 U/L and 6 ng/ml,
respectively.
Serologic analyses of anti-CII antibodies and IL-6
For quantification of serum IgG CII antibodies, 96-well
plates (Nunc, Roskilde, Denmark) were coated overnight
at 4°C with 1 μg/ml of native CII (SigmaAldrich, St Louis,
MO, USA). Plates were blocked for one hour at room
temperature using 0.5% BSA in PBS. Samples were diluted
in 0.5% BSA-PBS, added to the plates and incubated for
two hours at room temperature. Biotinylated F(ab’)2 frag-
ments of goat anti-mouse IgG (Jackson ImmunoResearch
Laboratories, Suffolk, UK) was used as secondary antibody.
Development was performed using extravidin peroxidase
(SigmaAldrich, St Louis, MO, USA) and the enzyme sub-
strate 3,3’,5,5’-Tetramethylbenzidine (TMB) (SigmaAl-
drich, St Louis, MO, USA). The reaction was stopped
using 1 M H2SO4 and the absorbance was measured at
405 nm in a SPECTRAmax spectrophotometer. Serum
levels of IL-6 were measured using a BD™ CBA mouse
inflammation kit (BD Biosciences, San Jose, CA, USA)
according to the manufacturer’s instructions. The detec-
tion limit for IL-6 was 5 pg/ml.
Flow cytometry analysis of bone marrow cells
One femur was flushed with 2 ml of PBS through the
bone cavity to harvest bone marrow cells. A Tris-buf-
fered 0.83% NH4Cl solution, pH 7.29 was used to lyse
erythrocytes, and the cells were then washed and re-sus-
pended in fluorescence-activated cell sorting (FACS)-
buffer (PBS supplemented with 1% fetal calf serum and
0.1% NaAz). Labelling of cell surface markers was per-
formed using anti-CD19 PE, anti-CD3 APC, anti-CD4
PerCP, and anti-CD8 FITC antibodies (BD, Franklin
Lakes, NJ, USA).
Statistical analysis
The Kruskall-Wallis test followed by a post hoc test were
used for comparisons between all groups in each experi-
ment. A P value less than 0.05 was considered significant.
The Graph Pad Prism 5 program was used for the statisti-
cal evaluations and calculations of area under the curve
(AUC), according to the manufacturer’s instructions.
Results
Treatment with Dex combined with E2 inhibits arthritis
and prevents osteoporosis
OVX or sham-operated female DBA/1-mice were immu-
nized for CIA in order to examine the anti-arthritic and
anti-osteoporotic properties of Dex combined with E2.
The mice were treated from the start of arthritis develop-
ment (day 23 post immunization) with Dex (125 μg/day),
E2 (1.0 μg/day), the combination of Dex + E2, or vehicle.
Body weights were continuously followed and the maxi-
mum changes in weight ranged from -3.3% to +12.3%, cal-
culated from the start of hormone treatment (day 23) until
the termination of the experiment (day 44) (Sham/Veh +
5.4%; OVX/Veh + 6.8%; OVX/E2 + 12.3%; OVX/Dex
-3.1%; OVX/Dex + E2 -3.3%).
Arthritis scores of the paws were evaluated every third
day. In the OVX vehicle control group, all mice had devel-
oped arthritis on day 29 after the first immunization
(Figure 1a), whereas the debut was delayed in the sham-
operated mice (100% frequency on day 44). Only 60% of
the OVX mice treated with E2 developed arthritis. Treat-
ment with Dex was highly protective and only 30% showed
signs of disease. All mice received treatment for five days
per week and clinical arthritis was seen at two time points
in the Dex treatment group, when the mice had not been
given Dex for two consecutive days. The symptoms
quickly abated with continued treatment. The mice treated
with the combination of both Dex and E2 did not display
any signs of arthritis at any time points during the study.
The frequency of arthritis differed significantly between
the OVX control and the E2, Dex, and Dex + E2 groups
from day 26 post immunization (P <0.01), and the differ-
ences were sustained throughout the treatment period. In
addition, calculation of the AUC for the frequency of
arthritis from day 23 to 44 (AUC(day 23-44)), showed that
combined treatment with Dex and E2 resulted in a five-
fold lower AUC(day 23-44) compared with Dex treatment
alone. (AUC(day 23-44): Sham/Veh = 1063, OVX/Veh =
1935, OVX/E2 = 690, OVX/Dex = 233, OVX/Dex +
E2 = 45).
The severity of the arthritic disease was ameliorated in
sham-operated mice, as well as in OVX mice treated
with E2, compared with OVX controls (Figure 1b). In
mice treated with Dex alone, mild signs of arthritis
c o u l db es e e no nt w oo c c a s i o n sw h e nt h em i c eh a dn o t
been given treatment for two days, (corresponding to
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ing the combination of Dex + E2 did not display any
signs of arthritis. OVX control mice had significantly
higher arthritic severity score (P<0.01) from day 26 post
immunization, compared with all other treatment
groups (OVX/E2, OVX/Dex and OVX/Dex + E2).
Histologic examination of the paw sections revealed
severe destruction of the joints from the vehicle-treated
control mice (median destruction score of 9.5 in OVX
vehicle mice) (Figure 1c). Sham-operated mice or OVX
mice treated with E2 displayed significantly lower histol-
ogy scores (median scores of 3.8 and 0.5, respecitvely).
Dex treatment alone or in combination with E2 resulted
in completely preserved joint structures, with median
destruction scores of 0.
As expected, the trabecular BMD was significantly
reduced in OVX mice compared with sham-operated
controls (Figure 1d). Although the arthritic disease was
successfully abated by treatment with Dex, the BMD was
not affected by Dex treatment compared with OVX con-
trols. However, combination of Dex and E2 treatment
resulted in a maintained BMD to the same extent as E2
alone. In conclusion, these results show that combined
treatment with glucocorticoids and estradiol successfully
inhibits the development of arthritis and the accompany-
ing joint destruction, and effectively preserves the BMD.
Treatment with Dex combined with Ral inhibits arthritis
and prevents osteoporosis
Since long-term treatment with estradiol is no longer
recommended due to severe side effects, we wanted to
examine if the combination of Ral with Dex treatment
could be as beneficial in inhibiting arthritis and protect-
ing the BMD as E2 + Dex in this model of arthritis. As
described in the materials and methods section, OVX or
sham-operated female DBA/1-mice were treated from
the start of arthritis development (day 22 post immuniza-
tion) with Dex (125 μg/day), Ral (120 μg/day), the combi-
nation of Dex + Ral, or controls. Body weights were
continuously followed and the maximum changes in
weight ranged from -5.5% to +3.7% calculated from the
start of hormone treatment (day 22) until the termination

A
D C
B
Figure 1 Addition of 17b-estradiol to dexamethasone-treated arthritic mice protects against osteoporosis induced by ovariectomy
and arthritis. Female sham-operated (n = 12) or ovariectomy (OVX) mice treated with vehicle (Veh; n = 10), 17b-estradiol (E2; n = 10),
dexamethasone (Dex; n = 9), or a combination of both Dex and E2 (n = 10) were used in order to evaluate the effects of treatment on arthritis
and bone mineral density (BMD). Treatment was administered five days per week, starting after the first appearance of arthritis (day 23), and
continued until the termination of the experiment (day 44). (a) Frequency and (b) severity of arthritis were evaluated every third day. Severity is
expressed as the mean ± standard deviation in each group. (c) Histologic scores of destruction in paw sections. (d) Trabecular BMD of one
femur. Scatter plots represent scores of individual mice, and bars show the median in each group. The non-parametric Kruskall-Wallis test with
post hoc comparison was used for statistical evaluation of all parameters, *P<0.05, **P<0.01, ***P<0.001.
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+3.7%; OVX/Ral +4.0%; OVX/Dex -5.5%; OVX/Dex +
Ral -1.2%).
Arthritis scores of the paws were evaluated every two
to three days. In the OVX vehicle control group, all
mice had developed arthritis on day 37 after the first
immunization (Figure 2a), whereas in the group of
sham-operated mice the arthritis debut was delayed
(100% frequency on day 49).O ft h eR a lt r e a t e dO V X
mice, 80% developed arthritis. Treatment with Dex was
highly protective, with a maximum of 40% ever showing
signs of disease. Similar to the previous experimental
setup (using Dex and E2), the mice treated with Dex
alone or the combination of Dex + Ral showed minor
flares of clinical arthritis at the time-points without
treatment for two days. The frequency of arthritis dif-
fered significantly between the OVX control group and
the Dex, and Dex + Ral groups from day 30 post immu-
nization (P<0.05). The differences were sustained
throughout the treatment period. In addition, calcula-
tion of the AUC for the frequency of arthritis during
the days 22 to 49 (AUC(day 22-49)), showed that com-
bined treatment with Dex and Ral resulted in a four-
fold lower AUC(day 22-49) compared with Dex-treatment
alone. (AUC(day 22-49): Sham/Veh = 890, OVX/Veh =
1,878, OVX/Ral = 1,335, OVX/Dex = 406, OVX/Dex
+Ral = 106).
As expected the severity of arthritis was ameliorated
in the Sham/Veh and OVX/Ral groups compared with
t h eO V X / V e h( F i g u r e2 b ) .I nm i c et r e a t e dw i t hD e x
alone or Dex + Ral, mild signs of arthritis could be seen
occasionally, but the severity of arthritis differed signifi-
cantly (P<0.05) for both groups as compared with OVX
controls from day 30, and the difference was sustained
throughout the treatment period. OVX control mice
had significantly higher (P<0.01) arthritic severity scores
from day 37 post immunization compared with the
other treatment groups (OVX/Ral, OVX/Dex and OVX/
Dex + Ral).
Severe destruction of the joints in the OVX control
mice (median destruction score of 7.5) (Figure 2c to 2d)
was revealed by histologic examination of the paws.
OVX mice treated with Ral displayed significantly lower
histology score (median score of 2.3). Dex-treatment
alone or in combination with Ral resulted in completely
preserved joint structure, with median destruction
scores of 0. In Figure 2d, representative pictures of the
H&E stained paw sections from each treatment group
are presented.
The trabecular BMD was significantly increased after
treatment with Ral, compared with OVX control mice
(Figure 3a), and the combination of Dex + Ral treatment
resulted in a maintained BMD to the same extent as
treatment with Ral alone. In Figure 3b representative 
D
Sham / Veh  OVX / Veh  OVX / Ral  OVX / Dex  OVX / Dex + Ral 
A B C
Figure 2 Treatment with dexamethasone alone or in combination with raloxifene reduces arthritis and protects against joint
destruction. Female sham-operated (n = 10) or ovariectomy (OVX) mice treated with vehicle (Veh; n = 9), raloxifene (Ral; n = 10),
dexamethasone (Dex; n = 9), or a combination of both Dex and Ral (n = 9) were used in order to evaluate the effects of treatment on arthritis
and bone mineral density (BMD). Treatment was administered five days per week, starting after the first appearance of arthritis (day 22), and
continued until the termination of the experiment (day 49). (a) Frequency and (b) severity were evaluated every two to three days. Severity is
expressed as the mean ± standard deviation in each group. (c) Histologic destruction scores of paw sections. Scatter plots show the scores of
individual mice, and bars show the median in each group. (d) Representative images of paw tissue sections, revealing the effects of treatment
on histologic features in each group. The non-parametric Kruskall-Wallis test with post hoc comparison was used for statistical evaluation of all
parameters, *P<0.05, **P<0.01, ***P<0.001.
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are shown. In conclusion, treatment with the combina-
tion of glucocorticoids and Ral totally abrogates the
development of arthritis, joint destruction, and trabecu-
lar bone loss.
Serological markers of cartilage destruction, bone
destruction, and inflammation decrease after treatment
with the combination of Dex and Ral
In CIA, the levels of COMP are elevated in serum due to
increased destruction of joint cartilage. Treatment with
Dex alone or the combination of Dex + Ral completely
inhibited any detection of COMP in serum of these mice
(Figure 4a). In order to measure bone resorption, col-
lagen type I cross-links (RatLaps) were analyzed in serum
(Figure 4b). As expected, the levels of RatLaps were sig-
nificantly decreased in mice treated with Ral, Dex, or the
combination of Dex + Ral, compared with OVX controls.
An increased level of anti-CII antibodies in serum is a
marker for an ongoing specific immune-activation
towards CII. Treatment with Dex or the combination of
Dex + Ral resulted in significantly lower levels of IgG
anti-CII antibodies in serum (Figure 4c). An increase in
the serum levels of IL-6 in CIA is a manifestation of the
general inflammatory disease. Mice in the OVX control
group displayed the most severe disease, and as expected
serum levels of IL-6 were increased in this group
compared with the mice treated with Dex or the combi-
nation of Dex + Ral (Figure 4d).
Dex-treatment reduces the levels of B cells, but not T
cells, in the bone marrow
Treatment with corticosteroids are known to induce
apoptosis of B lineage precursors in the bone marrow, as
well as of developing T cells in the thymus [17,18]. Flow
cytometry analysis was performed in order to investigate
the effects of treatment on bone marrow lymphocytes. As
expected, treatment with Dex or Dex + Ral resulted in a
substantial depletion of CD19 positive B cells in the bone
marrow (Figure 5a). A tendency towards lower levels of
CD3 positive T cells was detected after treatment with
Dex or Dex + Ral compared with OVX controls (Figure
5b). However, when CD4 and CD8 positive T cells were
studied separately, decreased levels of CD4 positive cells
could be detected in the Dex or Dex + Ral groups com-
pared with the OVX control group (Figure 5c), while
CD8 positive T cells were increased (Figure 5d).
Discussion
Estrogens can influence the pathogenesis of many
inflammatory diseases including RA [19]. The beneficial
effects of E2 on the development of murine experimen-
tal arthritis, and on osteoporosis associated with arthritis
and ovariectomy, have been previously well documented

B A
Sham / Veh  OVX / Veh 
OVX / Ral  OVX / Dex + Ral  OVX / Dex 
0  100 200 300 400 500 600  700  mg/cm3 
Figure 3 The combination of raloxifene with dexamethasone-treatment preserves the bone from osteoporosis induced by arthritis
and ovariectomy. Female sham-operated (n = 10) or ovariectomy (OVX) mice treated with vehicle (Veh; n = 9), raloxifene (Ral; n = 10),
dexamethasone (Dex; n = 8), or a combination of both Dex and Ral (n = 9) were used in order to evaluate the effects on trabecular bone
mineral density (BMD). Treatment was administered five days per week, starting after the first appearance of arthritis (day 22), and continued
until the termination of the experiment (day 49). (a) Scatter plots of individual data show the trabecular BMD of one femur and bars indicate the
median per group. Non-parametric Kruskall-Wallis test with post hoc comparison was used for statistical evaluation of all parameters, *P<0.05,
**P<0.01, ***P<0.001. (b) Representative peripheral quantitative computer tomography (pQCT) images of cross-sections of the femur showing the
BMD. The scale beneath indicates the density of the bone, from 0 (gray) to >750 mg/cm
3 (white).
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humans is associated with an increased risk of breast
cancer and thrombosis, and is therefore no longer
recommended [22,23]. The SERM Ral is approved for
treatment of patients with postmenopausal osteoporosis,
and is also approved as prophylaxis for invasive breast
cancer in the USA. However, studies have shown that
treatment with Ral increases the risk of deep venous
thrombosis and pulmonary embolism [24]. We recently
investigated if Ral was as beneficial as E2 on arthritis-
development and inflammation-induced bone loss.
Indeed, our studies revealed that Ral reduces the fre-
quency and severity of CIA, and preserves the bone
[11,12]. Those results were successfully repeated in this
study.
Glucocorticoids are potent anti-inflammatory and
immunosuppressive agents that are widely used to treat
both acute and chronic inflammation, such as RA. How-
ever, long-term treatment with glucocorticoids in
humans is associated with severe side effects including
metabolic disease, cardiovascular disease, avascular
necrosis, and osteoporosis [25-28]. The aim of the cur-
rent study was to investigate if addition of Ral or E2 to
ovariectomized Dex-treated arthritic mice could prevent
bone loss while simultaneously ameliorating the arthritic
disease. In clinical trials, the addition of estrogen replace-
ment therapy has been shown to have positive effects on
arthritis-associated and glucocorticoid-induced bone loss
[ 8 , 2 9 , 3 0 ] .I na d d i t i o n ,w eh a v ep r e v i o u s l ys h o w nt h a t
treatment with the combination of Dex + E2 have

B A
D C
Figure 4 Treatment with dexamethasone alone or in combination with raloxifene reduces the serum levels of COMP, RatLaps and
inflammatory markers in arthritic mice. Female sham-operated (n = 10) or ovariectomy (OVX) mice treated with vehicle (Veh; n = 9),
raloxifene (Ral; n = 10), dexamethasone (Dex; n = 9), or a combination of both Dex and Ral (n = 9) were used. Treatment was administered five
days per week, started after the first appearance of arthritis (day 22) and continued until the termination of the experiment (day 49). The effects
of the different treatments on cartilage destruction, bone destruction and inflammation were investigated. Serum levels of (a) COMP (cartilage
destruction), (b) RatLaps (bone destruction), and (c) anti-collagen type II (CII) antibodies were measured by ELISA. Serum levels of (d) IL-6 were
measured by cytometric bead assay. The detection limit for COMP was 2 U/L, for RatLaps 6 ng/ml, and for IL-6 5 pg/ml. The levels of anti-CII
antibodies are described in arbitrary units (AU). Scatter plots of individual data are presented and bars indicate the median. The non-parametric
Kruskall-Wallis test with post hoc comparison was used for statistical evaluation of all parameters, *P<0.05, **P<0.01, ***P<0.001.
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delayed type hypersensitivity reaction in mice [31]. How-
ever, the effects of combined treatment with Ral and Dex
on ovariectomized mice with inflammation-induced
osteoporosis have not previously been investigated.
In this study we show that treatment with Dex alone
significantly reduced the frequency and severity of arthri-
tis as well as the histologic evaluation scores of the joints
compared with control treated mice. The combination of
Dex + Ral or Dex + E2 completely abrogated any signs of
the disease and the median histologic joint destruction
score was kept at 0. Previous studies have demonstrated
that mice are susceptible to glucocorticoid-induced
osteoporosis [32,33]. Interestingly, in this experimental
setup we did not find any differences in trabecular BMD
between the OVX/Veh and the OVX/Dex group. This
could be due to the fact that all mice were ovariecto-
mized four weeks prior to the treatment start, and there-
fore likely already had low BMD at the start of the
treatment. In spite of this, the combined treatment with
Ral + Dex or E2 + Dex resulted in preserved BMD at
levels similar to the groups that received treatment with
Ral or E2 alone. COMP and RatLaps are markers for car-
tilage destruction and bone destruction, respectively.
Mice treated with Dex alone or Dex + Ral displayed low
or undetectable levels of COMP and RatLaps compared
with controls, reflecting the low levels of joint and bone
destruction in these groups.
The mechanisms for the anti-inflammatory effects of
glucocorticoids involve inhibition of vascular permeabil-
ity that occurs as an inflammatory response, as well as
decreased leukocyte migration into inflamed sites [34].

B
A
A
C D
B
Figure 5 Treatment with dexamethasone alone or in combination with raloxifene reduces the B cell frequency in bone marrow of
arthritic mice. Female sham-operated (n = 10) or ovariectomy (OVX) mice treated with vehicle (Veh; n = 9), raloxifene (Ral; n = 10),
dexamethasone (Dex; n = 9), or a combination of both Dex and Ral (n = 9) were used. Treatment was administered five days per week, started
after the first appearance of arthritis (day 22) and continued until the termination of the experiment (day 49). Flow cytometry analysis of bone
marrow cells was performed in order to investigate the effects of treatment on different lymphocyte phenotypes. Bone marrow cells from one
femur were harvested and labelled with antibodies against (a) CD19, (b) CD3, (c) CD4, or (d) CD8. Scatter plots of individual data are presented
and bars indicate the median in each group. The non-parametric Kruskall-Wallis test with post hoc comparison was used for statistical evaluation
of all parameters, *P<0.05, **P<0.01, ***P<0.001.
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Page 8 of 11The effects of estrogens on inflammation is a still unre-
solved paradox where estrogens can have both anti-
inflammatory and pro-inflammatory roles depending on,
for example, the immune stimulus, the concentration of
the estrogen, the target organ, the specific disease, and
the cell types involved [19]. The beneficial effects of
estrogen on arthritis are well documented [14,20,21];
however, the mechanisms are largely unknown. The
levels of anti-CII antibodies and IL-6 can be used as
markers for specific and generalized inflammation in
CIA. In this study the levels of anti-CII antibodies were
significantly decreased in mice treated with Dex alone
or with the combination of Dex + Ral compared with
controls. In addition, IL-6 was undetectable in the
majority of mice treated with Dex or Dex + Ral.
Glucocorticoids have pro-apoptotic effects on early
progenitor B cells in the bone marrow [18,35], as well as
on immature double positive T cells in the thymus
[17,35]. In contrast, mature single positive thymocytes
and peripheral T cells are less sensitive to glucocorticoid-
induced apoptosis [35]. We have previously shown that
treatment with E2 or Ral reduces the number of double
positive T cells in the thymus as well as the frequency of
B cells in the bone marrow [36,37]. As expected, in this
study Dex or Dex + Ral treatment resulted in a signifi-
cant reduction of CD19+ bone marrow cells compared
with controls (Figure 5a), while there was only a tendency
towards a reduction of CD3+ bone marrow cells (Figure
5b). Interestingly, when the CD3+ bone marrow cells
were divided into CD4+ and CD8+ T cells, Dex or Dex +
Ral treatment resulted in a decrease in CD4+ T cells and
an increase in CD8+ T cells compared with controls. The
reason for this discrepancy is unknown; however, we
speculate that mature CD4+ T cells are sensitive to glu-
cocorticoid-induced apoptosis while CD8+ T cells are
not.
The mechanisms behind the ameliorating effects of E2
or Ral on arthritis, and their anabolic effects on the skele-
t o n ,a r et oal a r g ee x t e n tu n k n o w n .W eh a v ep r e v i o u s l y
shown that signalling via estrogen receptor (ER) a,b u t
not ERb or GPR30, protects against ovariectomy-induced
trabecular bone loss and ameliorates CIA [38-41]. Ral has
been shown to bind with high affinity to ERa and func-
tions as an estrogen agonist in bone and on serum lipids,
but acts as an antagonist in uterus and breast tissue
[42-46]. It is therefore reasonable to believe that the pro-
tective effect on bone and the arthritic disease after treat-
ment with the combination of Dex and Ral is due to the
stimulating effect of Ral on ERa.
B i s p h o s p h o n a t e sr e d u c eb o n et u r n o v e rb ya l t e r i n g
osteoclast activity and are often considered first-line
therapy for glucocorticoid-induced and inflammation-
induced osteoporosis [47]. Given the results in this
study, we speculate that combined treatment with
glucocorticoids and Ral in postmenopausal RA patients
might be an excellent alternative to treatment with glu-
cocorticoids and bisphosphonates. The next step will be
to perform clinical studies in order to reveal the effects
of treatment with a combination of glucocorticoids and
Ral in postmenopausal RA patients.
Numerous new SERMs are currently undergoing clini-
cal development for the prevention and/or treatment of
postmenopausal osteoporosis [48]. For example, lasofox-
ifene was recently described to be associated with
reduced risks of fractures, ER-positive breast cancer,
coronary heart disease, and stroke in postmenopausal
patients with osteoporosis [49]. In addition, bazedoxi-
fene was shown to significantly reduce the risk of frac-
tures in postmenopausal women with osteoporosis, as
well as prevent bone loss and reduce bone turnover
equally well as Ral [50,51]. If these new SERMs have
similar anti-arthritic effects as Ral, and if the combina-
tion with glucocorticoids has similar effects as we have
shown in this study, remains to be investigated.
Conclusions
Results from this study show that addition of Ral or
estradiol to Dex treatment in arthritic mice prevents
generalized bone loss and development of arthritis. We
suggest that combined treatment with glucocorticoids
and Ral or other SERMs can be beneficial in order to
ameliorate the arthritic disease and simultaneously pre-
serve the bone in postmenopausal patients with RA.
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